课题基金 / 基金详情

REVERSE CHOLESTEROL TRANSPORT IN HUMANS

REVERSE CHOLESTEROL TRANSPORT IN HUMANS
人体中的胆固醇反向转运
批准号:
8585088
负责人:
RICHARD E. OSTLUND
金额:
$50.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-01-01 至 2015-11-30

项目摘要

项目成果

RICHARD E. OSTLUND的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary The central hypothesis of this proposal is that reverse cholesterol transport is related to coronary heart disease (CHD) risk. It is complementary to the concept that reduction of cholesterol biosynthesis with statin drugs prevents CHD, but it focuses on whole body cholesterol metabolism and kinetic cholesterol transport rather than on static levels of circulating lipoproteins. Although this is an old idea, it has not been adequately tested in humans because of lack of suitable methods. In this proposal we will apply innovative stable isotope and mass spectroscopic technology to study reverse cholesterol transport in human subjects. The first specific aim is to improve the preparation of intravenous deuterated cholesterol tracer, a critical limiting element in the study of whole body cholesterol metabolism. The second aim is to use that intravenous tracer, along with a different oral tracer, to partition fecal cholesterol into excreted endogenous cholesterol, unabsorbed dietary cholesterol and newly-synthesized cholesterol derived from the liver and intestine. Measurements will be made during consumption of a controlled diet provided by the metabolic kitchen. The pool size of the rapidly-mixing body cholesterol pool will be measured along with the fractional rate of cholesterol catabolism. These direct measures of reverse cholesterol transport will be correlated with plasma biomarkers and with metabolic covariates. The relation of reverse cholesterol transport to carotid intima-media thickness will be determined. The third specific aim will use similar methods to study the mechanism of action for the widely-used drug ezetimibe. Changes in fractional endogenous cholesterol excretion and related measures will be determined after ezetimibe or placebo treatment in a clinical trial. This work represents a new direction for cholesterol research with the potential to develop new and complementary methods of reducing CHD risk that can be added to diet and statin drug treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
REVERSE CHOLESTEROL TRANSPORT IN HUMANS
  • 批准号:
    8403769
  • 项目类别:
  • 资助金额:
    $48.98万
  • 财政年份:
    2012
  • 负责人:
    RICHARD E. OSTLUND
  • 依托单位:
REVERSE CHOLESTEROL TRANSPORT IN HUMANS
  • 批准号:
    8238613
  • 项目类别:
  • 资助金额:
    $55.49万
  • 财政年份:
    2012
  • 负责人:
    RICHARD E. OSTLUND
  • 依托单位:
DOSE EFFECTS OF DIETARY PHYTOSTEROLS ON CHOLESTEROL METABOLISM: A CONTROLLED
  • 批准号:
    8361452
  • 项目类别:
  • 资助金额:
    $1.08万
  • 财政年份:
    2011
  • 负责人:
    RICHARD E. OSTLUND
  • 依托单位:
THE EFFECTS OF PHYTOSTEROLS PRESENT IN NATURAL FOOD MATRICES ON CHOLESTEROL
  • 批准号:
    8361451
  • 项目类别:
  • 资助金额:
    $1.31万
  • 财政年份:
    2011
  • 负责人:
    RICHARD E. OSTLUND
  • 依托单位:
海外基金